目的:有研究证明聚乙二醇洛塞那肽(PEG-Loxe)对2型糖尿病(T2DM)患者的血糖和体重有显著的控制作用。但血脂(BLP)和血压(BP)的改善仍存在一定争议,需要更多的证据来验证这种影响。因此,本研究旨在对PEG-Loxe改善血糖(BG)的功效进行全面评估,BLP,BP,体重指数(BMI),2型糖尿病患者的体重(BW)为临床参考。方法:通过检索PubMed检索应用PEG-Loxe治疗T2DM的随机对照试验(RCT),科克伦图书馆,Embase,Medline,Scopus,WebofScience,中国国家知识基础设施,中国科学杂志,万方数据,和SinoMed数据库。结果指标包括BG,BLP,BP,BMI,和BW。采用RevMan5.3软件进行数据分析。结果:共确定了18项试验,涉及2,166例患者。在实验组1,260名患者单独或与其他降糖药一起接受PEG-Loxe,对照组906例患者接受安慰剂或其他降糖药。在总体分析中,PEG-Loxe显着降低糖化血红蛋白(HbA1c)的水平,空腹血糖(FPG),餐后2小时血糖(2小时PBG),BMI,BW与对照组比较。然而,对总胆固醇(TC)无明显影响,甘油三酯(TG),低密度脂蛋白胆固醇(LDL-C),高密度脂蛋白胆固醇(HDL-C),收缩压(SBP),和舒张压(DBP)。结论:PEG-Loxe对T2DM患者的降糖效果优于安慰剂,但不能显著改善TG,LDL-C,HDL-C,SBP,和DBP。而常规降糖药(CHD)与PEG-Loxe联合应用能更有效地改善HbA1c水平,FPG,2-hPBG,TC,TG,BMI,2型糖尿病患者BW与CHD比较。系统审查注册:www。inplasy.com,标识符INPLASY202350106。
Objective: Some studies have proved that polyethylene glycol loxenatide (PEG-Loxe) has significant effects on controlling blood glucose and body weight in patients with type 2 diabetes mellitus (T2DM), but there is still some controversy over the improvement of blood lipid profiles (BLP) and blood pressure (BP), and more evidences are needed to verify such effects. Therefore, this study was conducted to provide a comprehensive evaluation of the efficacy of PEG-Loxe in improving blood glucose (BG), BLP, BP, body mass index (BMI), and body weight (BW) in patients with T2DM for clinical reference. Methods: Randomized controlled trials (RCT) in which PEG-Loxe was applied to treat T2DM were retrieved by searching PubMed, Cochrane Library, Embase, Medline, Scopus, Web of Science, China National Knowledge Infrastructure, China Scientific Journal, Wanfang Data, and SinoMed databases. Outcome measures included BG, BLP, BP, BMI, and BW. RevMan 5.3 software was used to perform data analysis. Results: Eighteen trials were identified involving 2,166 patients. In experimental group 1,260 patients received PEG-Loxe alone or with other hypoglycemic agents, while in control group 906 patients received placebo or other hypoglycemic agents. In the overall analysis, PEG-Loxe significantly reduced the levels of glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), 2-h postprandial blood glucose (2-h PBG), BMI, and BW compared with control group. However, it had no obvious effect on total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), systolic blood pressure (SBP), and diastolic blood pressure (DBP). Conclusion: PEG-Loxe has better hypoglycemic effects compared with placebo in patients with T2DM, but could not significantly improved TG, LDL-C, HDL-C, SBP, and DBP. And the combination of conventional hypoglycemic drugs (CHD) and PEG-Loxe could more effectively improve the levels of HbA1c, FPG, 2-h PBG, TC, TG, BMI, and BW compared with CHD in T2DM patients. Systematic Review Registration: www.inplasy.com, identifier INPLASY202350106.